news
Sanofi makes $9.3b offer to acquire Medivation
28 April 2016 | By Victoria White, Digital Content Producer
Sanofi has made an unsolicited $9.3 billion offer to acquire Medivation, the maker of prostate cancer drug Xtandi...
List view / Grid view
Sanofi
news
Sanofi makes huge investment in the future of biologics
19 April 2016 | By Mandy Parrett, Editorial Assistant
Sanofi has announced plans to invest €300 million to expand its manufacturing and commercial capabilities at its site in Geel, Belgium.
news
World’s first public dengue immunisation programme starts
5 April 2016 | By Victoria White
Dengvaxia vaccinations of one million students from 6,000 public schools in the Philippines are to begin this year...
news
Positive topline results from two Phase III dupilumab studies
1 April 2016 | By Victoria White
Sanofi and Regeneron have announced positive topline results from two placebo-controlled Phase III studies evaluating investigational dupilumab in adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD).
news
Positive results for Praluent in patients undergoing LDL apheresis therapy
23 March 2016 | By Victoria White
Patients who added Praluent to their existing treatment regimen significantly reduced the frequency of their apheresis therapy by 75% compared to placebo....
news
Amgen wins drug patent case against Sanofi and Regeneron
17 March 2016 | By Victoria White
A jury has delivered a verdict in Amgen's favour in a trial on the validity of two Amgen patents that describe and claim monoclonal antibodies to PCSK9...
news
sarilumab demonstrates superiority to adalimumab in rheumatoid arthritis
11 March 2016 | By Victoria White
A Phase III study demonstrated that sarilumab was superior to adalimumab in improving signs and symptoms in patients with active RA...
news
Phase I/II data for neoGAA in Pompe disease presented
4 March 2016 | By Victoria White
Sanofi Genzyme says the safety and efficacy data from the NEO1 study support further development of neoGAA...
news
FDA accepts NDA for Sanofi’s combination of insulin glargine and lixisenatide
23 February 2016 | By Victoria White
This NDA submission is based on data from two Phase 3 studies of insulin glargine and lixisenatide in patients with with type 2 diabetes...
news
Heart UK questions absence of lipidologists after NICE limits cholesterol-busting drug use
12 February 2016 | By Victoria White
Heart UK has questioned why the NICE did not seek the expertise of lipidologists during its latest review of PCSK9 cholesterol-busting drugs...
news
NICE says ‘no’ to alirocumab in draft guidance
8 February 2016 | By Victoria White
NICE was concerned that alirocumab had not been compared with the combination therapy of ezetimibe plus a statin and that trials of the drug were not able to provide robust information on cardiovascular outcomes...
news
Muzammil Mansuri is Sanofi’s new Executive Committee member
5 February 2016 | By Victoria White
Mr. Mansuri joins Sanofi from Gilead Sciences and will take the position of Executive Vice President, Strategy & Business Development...
news
Sanofi and Boehringer Ingelheim announce business swap
15 December 2015 | By Victoria White
The proposed transaction would consist of an exchange of Sanofi animal health business (Merial) and Boehringer Ingelheim consumer healthcare (CHC) business...
news
Sanofi and Lexicon collaborate on sotagliflozin
6 November 2015 | By Victoria White
Sotagliflozin is an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 which could be a potential treatment option for people with diabetes...
news
Sanofi and Hanmi announce diabetes license agreement
5 November 2015 | By Victoria White
Sanofi and Hanmi have entered a worldwide license agreement to develop a portfolio of experimental, long-acting diabetes treatments...
